A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma.

Informazioni relative al progetto

CLINGLIO

ID dell’accordo di sovvenzione: 755179

DOI

10.3030/755179

Progetto chiuso

Data della firma CE 27 Novembre 2017

Data di avvio 1 Dicembre 2017

Data di completamento 31 Maggio 2022

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 6 155 125,00

Contributo UE

€ 6 155 125,00

Coordinato da

LAMINAR PHARMACEUTICALS SA
Spain

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Websites, patent fillings, videos etc. (2)

First regulatory approval of final version of study protocol

Approvals required for invitation / enrolment of first subject in at least one clinical centre: Ethic Committee, Competent Authority and National Data Protection Authority). Registration in Primary Registries in the WHO Registry Network (EU Clinical Trials Register (EU-CTR)).

Study team TCs, newsletters progress/issues reports

According to the communication plan specified in CT project plan (D4.2).Last publicaction will take place on month 36. We expect deliveries also in monots 6, 12, 24 and 30.

Documents, reports (6)

Protocols and laboratory manual for miRNAS, mRNA expression and RNAseq
Statistical protocols
Report on the status of posting results

Report on the status of posting results in the study registryies including timelines when final posting of results is scheduled after end of funding period To be scheduled for the time of expected results

Sample protocols for liquid biopsy biomarkers
Protocols for protein biomarker determinations

Protocols for protein biomarker determinations (GFAP, mTOR, pAkt, SMS1, SMS2, etc.).

Consititution of the different management bodies

Constitution of the different management bodies

Open Research Data Pilot (2)

Role of the membrane lipid composition and lipid genes in glioma cell proliferation

Expression and analysis and patient survival; (ii) Lipidomic and proteomic analysis of proliferating and quiescent glioma (U118) cells; (iii) potential biomarker determinations

SMS1 and SMS2 molecular modelling

(i) determination of SMS1 structure , (ii) determination of SMS2 structure, (iii) determination of SMS1-2OHOA and SMS2-2OHOA interactions, and (iv) determination of the structure and interaction with 2OHOA for specific mutants selected from other experiments in this WP

Other (1)

Public Web Site and Project Presentation

Design and maintenance of dedicated project web site with an offering of the typical electronic dissemination facilities

Demonstrators, pilots, prototypes (1)

Clinical Trial registration number

EudraCT

Pubblicazioni

Peer reviewed articles (6)

Study of the Interaction of a Novel Semi-Synthetic Peptide with Model Lipid Membranes

Autori: Lucia Sessa, Simona Concilio, Peter Walde, Tom Robinson, Petra S. Dittrich, Amalia Porta, Barbara Panunzi, Ugo Caruso, Stefano Piotto
Pubblicato in: Membranes, Numero 10/10, 2020, Pagina/e 294, ISSN 2077-0375
Editore: Molecular Diversity Preservation International
DOI: 10.3390/membranes10100294

Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues

Autori: Doralicia Casares, Pablo V. Escribá, Catalina Ana Rosselló
Pubblicato in: International Journal of Molecular Sciences, Numero 20/9, 2019, Pagina/e 2167, ISSN 1422-0067
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms20092167

The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA

Autori: Paula Fernández-García, Catalina A. Rosselló, Raquel Rodríguez-Lorca, Roberto Beteta-Göbel, Javier Fernández-Díaz, Victoria Lladó, Xavier Busquets, Pablo V. Escribá
Pubblicato in: Cancers, Numero 11/1, 2019, Pagina/e 88, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers11010088

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt

Autori: Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá
Pubblicato in: Oncotarget, Numero 10/26, 2019, ISSN 1949-2553
Editore: Impact Journals
DOI: 10.18632/oncotarget.26824

Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity

Autori: Wessal Massalha, Mark Markovits, Edward Pichinuk, Yael Feinstein-Rotkopf, Mark Tarshish, Kumudesh Mishra, Victoria Llado, Miguel Weil, Pablo V. Escriba, Or Kakhlon
Pubblicato in: Bioscience Reports, Numero 39/1, 2019, Pagina/e BSR20181661, ISSN 0144-8463
Editore: Kluwer Academic Publishers
DOI: 10.1042/bsr20181661

The Implications for Cells of the Lipid Switches Driven by Protein–Membrane Interactions and the Development of Membrane Lipid Therapy

Autori: Manuel Torres, Catalina Ana Rosselló, Paula Fernández-García, Victoria Lladó, Or Kakhlon, Pablo Vicente Escribá
Pubblicato in: International Journal of Molecular Sciences, Numero 21/7, 2020, Pagina/e 2322, ISSN 1422-0067
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21072322

Diritti di proprietà intellettuale

Patent (2)

ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG

Numero candidatura/pubblicazione: EP 09831504
Data: 2009-12-04
Candidato/i: UNIVERSITAT DE LES ILLES BALEARS

USE OF HYDROXYOLEIC ACID AND SIMILAR COMPOUNDS IN THE PRODUCTION OF MEDICAMENTS

Numero candidatura/pubblicazione: EP 02783094
Data: 2002-10-09
Candidato/i: UNIVERSITAT DE LES ILLES BALEARS